- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03835754
Heart EXPAND Continued Access Protocol
July 24, 2023 updated by: TransMedics
Heart Expand Continued Access Protocol
The OCS™ Heart System will be used to preserve and assess donor hearts that do not meet current standard donor heart acceptance criteria for transplantation in this continued access protocol.
Study Overview
Detailed Description
To provide additional data evaluating the safety and effectiveness of the OCS™ Heart System to preserve and assess donor hearts that do not meet current standard donor heart acceptance criteria (as identified above) for transplantation to potentially improve donor heart utilization for transplantation at a range of transplant centers in the U.S. and to permit patients and physicians access to the OCS Heart System while a PMA application is under preparation and review.
Study Type
Interventional
Enrollment (Actual)
75
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Los Angeles, California, United States, 90211
- Cedars-Sinai
-
Palo Alto, California, United States, 94304
- Stanford University
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Yale New Haven Hospital
-
-
Florida
-
Orlando, Florida, United States, 32803
- AdventHealth Orlando
-
-
Indiana
-
Indianapolis, Indiana, United States, 46260
- St. Vincent Cardiovascular Research Institute
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55407
- Minneapolis Heart Institute
-
-
New York
-
New York, New York, United States, 10032
- Nyph/Cumc
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt Medical Center
-
-
Washington
-
Seattle, Washington, United States, 98195
- University Of Washington Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria (DONOR):
At least one of the following:
- Expected total cross-clamp time of ≥ 4 hours
- Expected total cross-clamp time of ≥ 2 hours PLUS one or more of the following risk factors Donor age 45-55 years, inclusive, with no coronary catheterization data; or Donor age ≥ 55 years; or Left ventricular septal or posterior wall thickness of >12 mm, but ≤ 16 mm; or Reported down time of ≥ 20 min, with stable hemodynamics at time of final assessment; or Left heart ejection fraction (EF) ≥ 40%, but ≤ 50% at time of acceptance of offer; or Donor angiogram with luminal irregularities with no significant CAD (≤ 50%); or History of carbon monoxide poisoning with good cardiac function at time of donor assessment; or Social history of alcoholism with good cardiac function at time of donor assessment; or History of diabetes without significant CAD (≤ 50%) on angiogram.
Exclusion
- CAD with > 50% stenosis on angiogram, or
- Cardiogenic shock or myocardial infarction, or
- EF consistently < 40%, or
- Significant valve disease except for competent bicuspid aortic valve.
Eligibility Criteria (RECIPIENT)
- Registered primary heart transplant candidate
- Age >18 years old
- Written informed consent. Exclusion
- Prior solid organ or bone marrow transplant
- Chronic use of hemodialysis or renal replacement therapy for diagnosis of chronic renal insufficiency requiring dialysis
- Multi-organ transplant.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: OCS Preservation
|
The OCS Heart System preserves the heart in a near-physiological, beating state by perfusing the heart with a warmed, donor-blood based perfusate that is supplemented with nutrients and oxygen in a controlled and protected environment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Survival
Time Frame: 30 days
|
Patient survival post transplant
|
30 days
|
Absence of severe PGD
Time Frame: 24 hours post heart transplant
|
Absence of severe primary heart graft dysfunction of left and/or right ventricle in the first 24 hours post transplant
|
24 hours post heart transplant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Survival
Time Frame: 30 days
|
Patient and graft survival
|
30 days
|
Incidence of severe PGD
Time Frame: 24 hours post transplant
|
Incidence of severe primary heart graft dysfunction of left and/or right ventricle in the first 24 hours post heart transplant
|
24 hours post transplant
|
Donor heart utilization rate
Time Frame: 24 hours post-transplant
|
The proportion of eligible donor hearts that were successfully transplanted after preservation and assessment on the OCS Heart System
|
24 hours post-transplant
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Survival
Time Frame: 6 and 12 months
|
Patient survival at 6 and 12 months post-transplant
|
6 and 12 months
|
Incidence of primary graft failure
Time Frame: Through 12 months post transplant
|
Incidence of primary graft failure requiring re-transplantation
|
Through 12 months post transplant
|
ICU stay
Time Frame: Through hospital discharge, estimated to be 14 days
|
Duration of initial post-transplant ICU stay in days
|
Through hospital discharge, estimated to be 14 days
|
Hospital stay
Time Frame: Through hospital discharge, estimated to be 30 days
|
Duration of initial post-transplant hospital stay in days
|
Through hospital discharge, estimated to be 30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 17, 2019
Primary Completion (Actual)
September 15, 2021
Study Completion (Actual)
August 12, 2022
Study Registration Dates
First Submitted
January 22, 2019
First Submitted That Met QC Criteria
February 7, 2019
First Posted (Actual)
February 11, 2019
Study Record Updates
Last Update Posted (Actual)
July 27, 2023
Last Update Submitted That Met QC Criteria
July 24, 2023
Last Verified
December 1, 2022
More Information
Terms related to this study
Other Study ID Numbers
- OCS-CAR-121918
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Transplant
-
University Health Network, TorontoNot yet recruitingSolid Organ Transplant | Liver Transplant | Kidney Transplant | Heart Transplant
-
National Institute of Allergy and Infectious Diseases...Clinical Trials in Organ TransplantationTerminatedHeart Transplantation | Heart Transplant | Primary Heart TransplantUnited States
-
University of MichiganHoffmann-La RocheCompletedKidney Transplant Recipient | Heart Transplant RecipientUnited States
-
Mayo ClinicNational Heart, Lung, and Blood Institute (NHLBI)CompletedLung Transplant | Self-management | Heart TransplantUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Duke University; St. Paul's Hospital... and other collaboratorsActive, not recruitingHeart Diseases | Heart Failure | Transplant; Failure, Heart | Heart Transplant Failure and Rejection | Heart Failure,Congestive | Transplant FailureCanada, United States
-
Juan Francisco Delgado JimenezFundación Centro Nacional de Investigaciones Cardiovasculares Carlos IIIActive, not recruitingAntibody-mediated Rejection | Heart Transplant Rejection | Transplant FailureSpain
-
TransMedicsRecruiting
-
Fondazione Don Carlo Gnocchi OnlusRecruiting
-
Xie MingxingShanghai Zhongshan Hospital; Second Affiliated Hospital, School of Medicine... and other collaboratorsNot yet recruiting
-
TransMedicsActive, not recruiting
Clinical Trials on OCS Heart System
-
Hannover Medical SchoolRecruiting
-
TransMedicsActive, not recruiting
-
TransMedicsRecruiting
-
TransMedicsActive, not recruiting
-
TransMedicsCompletedOCS Lung SystemUnited States, Germany, Belgium
-
TransMedicsCompletedBronchiolitis ObliteransUnited States, Canada, Italy, Australia, Belgium, France, Germany, Spain, United Kingdom